China-based pharmaceutical distribution giant Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607) has entered into a strategic partnership with compatriot firm Asymchem Laboratories (Tianjin) Co., Ltd (SHE: 002821), a leading Contract Development and Manufacturing Organization (CDMO). This collaboration will span synthetic biotechnology, continuous reaction technology, and the development and production of both small and large molecule drugs, as well as formulation research and development.
Scope of the Partnership
The partnership will also focus on the joint development of active pharmaceutical ingredient (API) business. Asymchem will utilize its independently developed advanced manufacturing technologies and extensive experience in translating scientific and technological achievements into practical applications. This move is aimed at accelerating the export of advanced technologies and equipment, including continuous reaction and synthetic biotechnology, to support SPH’s research and development efforts, enhance existing production processes, and promote its investigational pipeline.
Financial Details
The financial terms of the partnership have not been disclosed, reflecting the focus on the strategic and operational synergies that the collaboration is expected to generate.-Fineline Info & Tech
